ClinicalTrials.gg
CompletedNCT05855616Updated Feb 7, 2024Results posted

Chlorhexidine Dressings for Hemodialysis Catheter Exit Site Care: Comparative Study

An interventional study of Group "chlorhexidine dressing" and Group "solution" in Hemodialysis Catheter Infection, sponsored by Hospital Universitario Marqués de Valdecilla. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Hospital Universitario Marqués de Valdecilla · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Nov 2020, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the rate of hemodialysis catheter-related infections according to the treatment regimen: chlorhexidine gluconate dressing or chlorhexidine solution.

Read the detailed description

Introduction: The use of CVC as a vascular access for haemodialysis is associated with increased morbidity and mortality (up to 10 times higher in a patient with a CVC compared to an arteriovenous fistula), contributing to poorer patient outcomes and increased haemodialysis-related costs.

Aim: To compare the rate of catheter-related infections (bacteraemia, exit site infection and tunelitis) between haemodialysis catheter exit site dressing with 2% chlorhexidine gluconate self-adhesive semi-permeable polyurethane dressings (AGCD); and dressing with 2% chlorhexidine solution and covered with self-adhesive semi-permeable polyurethane dressing (PD).

Methods: A randomized clinical trial will be conducted to compare the occurrence of local and systemic infections related to hemodialysis catheter. Two care groups will be formed in which AGCD and PD dressings will be used. In addition, other clinical variables, patient satisfaction and dressing-related skin alterations will also be analyzed.

Scientific relevance: Infectious complications related with hemodialysis catheter have an increased morbidity, mortality and incremented costs.

Key words: hemodialysis, Central Venous Catheters, Bacteremia, exit site infection, tunnel infection, chlorhexidine gluconate dressing.

02

Conditions studied

  • Hemodialysis Catheter Infection
03

In context

Lead sponsor

Hospital Universitario Marqués de Valdecilla is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be included in the haemodialysis programme in our unit.
  • Being a carrier of a tunneled central venous catheter as vascular access.
  • Remain on haemodialysis treatment for at least 3 months in our unit.
  • Consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Allergy or to chlorhexidine or intolerance to polyurethane dressing
  • Active catheter-related infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Group "chlorhexidine dressing"

    CHG Chlorhexidine Gluconate dressing

    Device: Group "chlorhexidine dressing"

  • Other
    Group "solution"

    2% aqueous-based chlorhexidine solution and covering with a semi-permeable self-adhesive polyurethane dressing.

    Other: Group "solution"

Interventions

  • DeviceGroup "chlorhexidine dressing"

    Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.

  • OtherGroup "solution"

    Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.

06

What researchers measure

Primary outcomes

  1. Bacteraemia Rate

    presence of fever (body temperature ≥38°C) together with a positive blood culture , with no other source of infection.

    Time frame: 3 months

  2. Exit Site Infection Rate

    positive culture of pericatheter smear together with presence of inflammatory signs limited to 2 cm around the cutaneous exit site, without upper extension towards the catheter cuff.

    Time frame: 3 months

  3. Tunnelitis Rate

    occurrence of inflammatory signs extending beyond 2 cm from the cutaneous exit site and into the subcutaneous tract of the catheter (tunnelitis). It may or may not be associated with fever and bacteraemia, and may be accompanied by purulent exudate through the cutaneous exit site.

    Time frame: 3 months

Secondary outcomes

  1. Patient Satisfaction Rate

    SCALE 18: Degree of perception of positive expectations, of the NOC taxonomy will be used. It will be evaluated using a 5-point Likert-type scale where 1- Not at all satisfied, 2- Somewhat satisfied, 3- Moderately satisfied, 4- Very satisfied, 5- Completely satisfied.

    Time frame: 3 months

  2. Percentage of Hemodialysis Sessions With Skin Lesions

    They will be assessed at each hemodialysis session, using the NOC taxonomy Skin lesions, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.

    Time frame: 3 months

  3. Percentage of Hemodialysis Sessions With Dressing-related Skin Erythema Rate

    They will be assessed at each hemodialysis session, using the NOC taxonomy Erytema, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.

    Time frame: 3 months

07

Results

Posted Feb 7, 2024
Limitations and caveats
The main limitation is the limited follow-up time

Participant flow

Participant flow — Overall Study
MilestoneGroup "Chlorhexidine Dressing"Group "Solution"
Started2627
Completed2525
Not completed12
Withdrew: Lost to follow-up12

Outcome measures

PrimaryBacteraemia Rate

presence of fever (body temperature ≥38°C) together with a positive blood culture , with no other source of infection.

Time frame:
3 months
Reported as:
Number · episodes
Bacteraemia Rate
episodesControl Arm "Group Solution"Experimental Arm "Chlorhexidine Dressing"
Bacteraemia Rate21
Statistical analysis
  • Control Arm "Group Solution" vs Experimental Arm "Chlorhexidine Dressing" · t-test, 1 sided · p = 1.00 · Odds ratio (or): 0.533 · 95% CI 0.048 to 5.892
PrimaryExit Site Infection Rate

positive culture of pericatheter smear together with presence of inflammatory signs limited to 2 cm around the cutaneous exit site, without upper extension towards the catheter cuff.

Time frame:
3 months
Reported as:
Number · episodes
Exit Site Infection Rate
episodesGroup "Chlorhexidine Dressing"Group "Solution"
Exit Site Infection Rate212
Statistical analysis
  • Group "Chlorhexidine Dressing" vs Group "Solution" · t-test, 1 sided · p = 0.013 · Odds ratio (or): 0.176 · 95% CI 0.039 to 0.790
PrimaryTunnelitis Rate

occurrence of inflammatory signs extending beyond 2 cm from the cutaneous exit site and into the subcutaneous tract of the catheter (tunnelitis). It may or may not be associated with fever and bacteraemia, and may be accompanied by purulent exudate through the cutaneous exit site.

Time frame:
3 months
Reported as:
Number · episodes
Tunnelitis Rate
episodesGroup "Chlorhexidine Dressing"Group "Solution"
Tunnelitis Rate00
SecondaryPatient Satisfaction Rate

SCALE 18: Degree of perception of positive expectations, of the NOC taxonomy will be used. It will be evaluated using a 5-point Likert-type scale where 1- Not at all satisfied, 2- Somewhat satisfied, 3- Moderately satisfied, 4- Very satisfied, 5- Completely satisfied.

Time frame:
3 months
Reported as:
Count of participants · Participants
Patient Satisfaction Rate
ParticipantsGroup "Chlorhexidine Dressing"Group "Solution"
Not at all satisfied00
Somewhat satisfied02
Moderately satisfied31
Very satisfied105
Completely satisfied1217
Statistical analysis
  • Group "Chlorhexidine Dressing" vs Group "Solution" · Chi-squared, Corrected · p = 0.137
SecondaryPercentage of Hemodialysis Sessions With Skin Lesions

They will be assessed at each hemodialysis session, using the NOC taxonomy Skin lesions, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.

Time frame:
3 months
Reported as:
Number · percentage of sessions
Percentage of Hemodialysis Sessions With Skin Lesions
percentage of sessionsGroup "Chlorhexidine Dressing"Group "Solution"
Not Skin Lesions99.199
Skin Lesions0.91
Statistical analysis
  • Group "Chlorhexidine Dressing" vs Group "Solution" · Chi-squared, Corrected · p = 0.764
SecondaryPercentage of Hemodialysis Sessions With Dressing-related Skin Erythema Rate

They will be assessed at each hemodialysis session, using the NOC taxonomy Erytema, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.

Time frame:
3 months
Reported as:
Number · percentage of sessions
Percentage of Hemodialysis Sessions With Dressing-related Skin Erythema Rate
percentage of sessionsGroup "Chlorhexidine Dressing"Group "Solution"
Not Erythema98.299.2
Erythema1.80.8
Statistical analysis
  • Group "Chlorhexidine Dressing" vs Group "Solution" · Chi-squared, Corrected · p = 0.055

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group "Chlorhexidine Dressing"0/25 (0%)0/25 (0%)0/25 (0%)
Group "Solution"0/25 (0%)0/25 (0%)0/25 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group "Solution"Group "Chlorhexidine Dressing"Total
Mean70 ± 1368 ± 1569 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)Group "Solution"Group "Chlorhexidine Dressing"Total
Female111223
Male141327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group "Solution"Group "Chlorhexidine Dressing"Total
Hispanic or Latino252550
Not Hispanic or Latino000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Group "Solution"Group "Chlorhexidine Dressing"Total
Spain252550
08

Study locations

1 site
  • Raquel Pelayo Alonso
    Santander, Cantabria 39008, Spain
09

References and documents

Publications

  • Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordoir J, Van Biesen W. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). NDT Plus. 2010 Jun;3(3):234-246. doi: 10.1093/ndtplus/sfq041. No abstract available. PubMed 30792802 ↗
  • Wang K, Wang P, Liang X, Lu X, Liu Z. Epidemiology of haemodialysis catheter complications: a survey of 865 dialysis patients from 14 haemodialysis centres in Henan province in China. BMJ Open. 2015 Nov 20;5(11):e007136. doi: 10.1136/bmjopen-2014-007136. PubMed 26589425 ↗
  • Righetti M, Palmieri N, Bracchi O, Prencipe M, Bruschetta E, Colombo F, Brenna I, Stefani F, Amar K, Scalia A, Conte F. Tegaderm CHG dressing significantly improves catheter-related infection rate in hemodialysis patients. J Vasc Access. 2016 Sep 21;17(5):417-422. doi: 10.5301/jva.5000596. Epub 2016 Aug 1. PubMed 27516139 ↗
  • Wei L, Li Y, Li X, Bian L, Wen Z, Li M. Chlorhexidine-impregnated dressing for the prophylaxis of central venous catheter-related complications: a systematic review and meta-analysis. BMC Infect Dis. 2019 May 16;19(1):429. doi: 10.1186/s12879-019-4029-9. PubMed 31096918 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Jul 2022, 20 months.

Results were first posted in Feb 2024, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
May 11, 2023
StartActual
Nov 1, 2020
Primary completionActual
Jul 1, 2022
CompletionActual
Dec 30, 2022
Results first posted
Feb 7, 2024
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05855616
Lead sponsor
Hospital Universitario Marqués de Valdecilla
Responsible party
Raquel Pelayo Alonso (Head nurse of the Nephrology department, RN., Hospital Universitario Marqués de Valdecilla) — Principal investigator
First posted
May 11, 2023
Start date
Nov 1, 2020
Primary completion
Jul 1, 2022
Completion
Dec 30, 2022
Results posted
Feb 7, 2024
Last update
Feb 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion